^
Association details:
| Biomarker: | VHL mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
Excerpt:
The median OS for everolimus was 22 months, which is the longest reported for this drug to date….The treatment effect was similar across most subgroups, favoring the everolimus treatment arm. A trend toward a greater benefit from everolimus was seen in patients with putative inactivating mutations in VHL1, as described in more detail in Fig 3B.
DOI:
10.1200/JCO.2015.64.8808
